Literature DB >> 20010338

Hydrochlorothiazide versus chlorthalidone in the management of hypertension.

Kimberly M Neff1, James J Nawarskas.   

Abstract

Thiazide diuretics are a mainstay for the treatment of hypertension. Although there are several thiazide diuretics currently available, hydrochlorothiazide (HCTZ) continues to be the most popular thiazide used for treating high blood pressure. This is despite several clinical trials that have used and documented the benefits of chlorthalidone for hypertension management. In terms of blood pressure lowering, both HCTZ and chlorthalidone appear to be very effective. Head-to-head studies have shown trends favoring chlorthalidone as a more effective blood pressure lowering agent compared with HCTZ, but statistical significance in this regard has not been consistently demonstrated. Also unclear is the relative benefits of these 2 drugs with regards to reducing clinical complications of hypertension, namely cardiovascular morbidity and mortality. Whereas there is more aggregate clinical trial data documenting the benefits of chlorthalidone compared with HCTZ in terms of hard clinical outcomes, these trials are not direct comparisons and can only be used to fuel the debate as to which of the 2 thiazides are better. From a safety perspective, hypokalemia is a risk with any of the thiazide diuretics and has been shown to be dose-related. However, at equipotent dosages, the incidence of hypokalemia between chlorthalidone and HCTZ appears comparable. The available evidence therefore supports both HCTZ and chlorthalidone as safe and effective drugs for treating hypertension. Although there are favorable trends both in terms of antihypertensive efficacy as well as clinical outcomes data with chlorthalidone compared with HCTZ, the results are not conclusive, and as such may not be enough to shift the treatment paradigm in favor of chlorthalidone, given the comfort level that most prescribers have with HCTZ. A head-to-head study looking at hard clinical outcomes, which may or may not ever be performed, may be the only way to resolve the ongoing debate as to which is the preferred thiazide for treating hypertension.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20010338     DOI: 10.1097/CRD.0b013e3181c61b52

Source DB:  PubMed          Journal:  Cardiol Rev        ISSN: 1061-5377            Impact factor:   2.644


  10 in total

Review 1.  "Targeted" consent for pragmatic clinical trials.

Authors:  David Wendler
Journal:  J Gen Intern Med       Date:  2015-01-14       Impact factor: 5.128

Review 2.  Which diuretic is the preferred agent for treating essential hypertension: hydrochlorothiazide or chlorthalidone?

Authors:  F Wilford Germino
Journal:  Curr Cardiol Rep       Date:  2012-12       Impact factor: 2.931

3.  Adverse effect profile of trichlormethiazide: a retrospective observational study.

Authors:  Yasuo Takahashi; Yayoi Nishida; Tomohiro Nakayama; Satoshi Asai
Journal:  Cardiovasc Diabetol       Date:  2011-05-23       Impact factor: 9.951

4.  Integrated control of hypertension by olmesartan medoxomil and hydrochlorothiazide and rationale for combination.

Authors:  Henry A Punzi
Journal:  Integr Blood Press Control       Date:  2011-12-07

5.  Race-Specific Comparisons of Antihypertensive and Metabolic Effects of Hydrochlorothiazide and Chlorthalidone.

Authors:  Lakshmi Manasa S Chekka; Arlene B Chapman; John G Gums; Rhonda M Cooper-DeHoff; Julie A Johnson
Journal:  Am J Med       Date:  2021-01-09       Impact factor: 5.928

6.  Pragmatic clinical trials embedded in healthcare systems: generalizable lessons from the NIH Collaboratory.

Authors:  Kevin P Weinfurt; Adrian F Hernandez; Gloria D Coronado; Lynn L DeBar; Laura M Dember; Beverly B Green; Patrick J Heagerty; Susan S Huang; Kathryn T James; Jeffrey G Jarvik; Eric B Larson; Vincent Mor; Richard Platt; Gary E Rosenthal; Edward J Septimus; Gregory E Simon; Karen L Staman; Jeremy Sugarman; Miguel Vazquez; Douglas Zatzick; Lesley H Curtis
Journal:  BMC Med Res Methodol       Date:  2017-09-18       Impact factor: 4.615

Review 7.  Thiazides in the management of hypertension in older adults - a systematic review.

Authors:  Christina Sommerauer; Neha Kaushik; Adrine Woodham; Anna Renom-Guiteras; Yolanda V Martinez; David Reeves; Ilkka Kunnamo; Thekraiat Al Qur An; Steffen Hübner; Andreas Sönnichsen
Journal:  BMC Geriatr       Date:  2017-10-16       Impact factor: 3.921

Review 8.  Pharmacogenomics of Hypertension Treatment.

Authors:  Jacek Rysz; Beata Franczyk; Magdalena Rysz-Górzyńska; Anna Gluba-Brzózka
Journal:  Int J Mol Sci       Date:  2020-07-01       Impact factor: 5.923

Review 9.  Pharmacogenomics of amlodipine and hydrochlorothiazide therapy and the quest for improved control of hypertension: a mini review.

Authors:  Rabia Johnson; Phiwayinkosi Dludla; Sihle Mabhida; Mongi Benjeddou; Johan Louw; Faghri February
Journal:  Heart Fail Rev       Date:  2019-05       Impact factor: 4.214

10.  Genome Wide Analysis Approach Suggests Chromosome 2 Locus to be Associated with Thiazide and Thiazide Like-Diuretics Blood Pressure Response.

Authors:  Sonal Singh; Caitrin W McDonough; Yan Gong; Kent R Bailey; Eric Boerwinkle; Arlene B Chapman; John G Gums; Stephen T Turner; Rhonda M Cooper-DeHoff; Julie A Johnson
Journal:  Sci Rep       Date:  2019-11-21       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.